The CSL Limited (ASX: CSL) share price rocketed 15.6% higher in August, aided by a full-year profit result that beat its upgraded guidance from May.
Full-year profit for the 12 months ending 30th June 2018 of $1729 million was delivered, up 29% on the same period a year earlier.
The vaccines and blood products supplier said sales revenue for the year to June 30 rose 14.7% to $US7.59 billion.
On a per-share basis, the company said it had a profit of 382 cents. This compares with a profit of 294 cents per share in the corresponding period last year. The company declared a full year dividend for the period of 172 cents per share, an increase of 26%.